Show simple item record

dc.contributor.authorRingen, Petter Andreas
dc.contributor.authorLund-Stenvold, Elisabeth Haug
dc.contributor.authorAndreassen, Ole
dc.contributor.authorGaarden, Torfinn Lødøen
dc.contributor.authorHartberg, Cecilie Bhandari
dc.contributor.authorJohnsen, Erik
dc.contributor.authorMyklatun, Silje
dc.contributor.authorOsnes, Kåre
dc.contributor.authorSørensen, Kirsten
dc.contributor.authorSørensen, Kjetil
dc.contributor.authorVaaler, Arne
dc.contributor.authorTonstad, Serena
dc.contributor.authorEngh, John
dc.contributor.authorHøye, Anne
dc.description.abstractPurpose Cardiometabolic disease in patients with severe mental illness is a major cause of shortened life expectancy. There is sparse evidence of real-world clinical risk prevention practice. We investigated levels of assessments of cardiometabolic risk factors and risk management interventions in patients with severe mental illness in the Norwegian mental health service according to an acknowledged international standard. Methods We collected data from 264 patients residing in six country-wide health trusts for: (a) assessments of cardiometabolic risk and (b) assessments of levels of risk reducing interventions. Logistic regressions were employed to investigate associations between risk and interventions. Results Complete assessments of all cardiometabolic risk variables were performed in 50% of the participants and 88% thereof had risk levels requiring intervention according to the standard. Smoking cessation advice was provided to 45% of daily smokers and 4% were referred to an intervention program. Obesity was identified in 62% and was associated with lifestyle interventions. Reassessment of psychotropic medication was done in 28% of the obese patients. Women with obesity were less likely to receive dietary advice, and use of clozapine or olanzapine reduced the chances for patients with obesity of getting weight reducing interventions. Conclusions Nearly nine out of the ten participants were identified as being at cardiometabolic high risk and only half of the participants were adequately screened. Women with obesity and patients using antipsychotics with higher levels of cardiometabolic side effects had fewer adequate interventions. The findings underscore the need for standardized recommendations for identification and provision of cardiometabolic risk reducing interventions in all patients with severe mental illness.en_US
dc.publisherTaylor & Francisen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.titleQuality of clinical management of cardiometabolic risk factors in patients with severe mental illness in a specialist mental health care settingen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holder© 2022 The Author(s).en_US
dc.source.journalNordic Journal of Psychiatryen_US
dc.identifier.citationNordic Journal of Psychiatry. 2022.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal